Neither Nogo-A nor MAG or OMgp concentrations were significantly different, in serum or CSF, between patients with IDH1 wild-type astrocytic brain tumour compared to patients with IDH1 mutant astrocytic brain tumour (data not shown), which may indirectly indicate that the tested molecules could not be recognized as prognostic biomarkers of brain tumours. The gene discussed is IDH1; the disease is brain neoplasm.